Download Free Sample
Buy Now
Table of Contents
1.1. Context
1.2. Project Objectives
1.3. Project Approach
2.1. Overall Intellectual Property Landscape (Simply Family)
2.2. Intellectual Property Valuation Analysis
2.3. Prior Art Search Expressions
2.4. Analysis of Patent Applications
2.5. Analysis of Granted Patents
2.6. Claim Analysis of Granted Patents
2.7. Pockets of Innovation
2.8. White Spaces
2.9. Future Outlook
3.1. Overview of Lipid Nanoparticles
3.2. Historical Development of Lipid Nanoparticles
3.3. Type of Lipid Nanoparticles used in Drug Delivery
3.4. Lipid Nanoparticle Production Methods
3.5. Advantages of Lipid Nanoparticles
3.6. Key Application Areas of Lipid Nanoparticles
3.7. Challenges Associated with Lipid Nanoparticles Manufacturing
3.8. Future Perspective
4.1. Chapter Overview
4.2. Methodology
4.3. Key Objectives
4.4. Lipid Nanoparticles in Drug Delivery: Overall IP Landscape
4.4.1. Year-wise Trend of Patents
4.4.2. Analysis by Patent Jurisdiction
4.4.3. Analysis by Type of Patent
4.4.4. Analysis by Kind Code
4.4.5. Analysis by Time to Expiry
4.5. Lipid Nanoparticles in Drug Delivery: Simple Patent Family IP Landscape
4.5.1. Year-wise Trend of Patents
4.5.2. Analysis by Validity of Claims
4.5.3. Analysis by Type of Patent
4.5.4. Analysis by Kind Code
4.5.5. Analysis by Time to Expiry
4.5.6. Analysis by Patent Jurisdiction
4.5.7. Simple Family Lipid Nanoparticles in Drug Delivery IP Landscape: Innovation Type
4.5.7.1. Analysis of Patent Applications by Innovation Type
4.5.7.2. Analysis of Granted Patents by Innovation Type
5.1. Chapter Overview
5.2. Methodology
5.3. Key Objectives
5.4. Frequently Used Prior Art Search Expressions
5.4.1. Key IP Trends Associated with the Word - Method
5.4.1.1. Analysis by Annual Number of Patents
5.4.1.2. Analysis by Type of Patent
5.4.1.3. Analysis by Time to Expiry
5.4.1.4. Analysis by Patent Jurisdiction
5.4.1.5. Other Key Associated Words / Phrases
** Similar details are presented for other below mentioned keywords based on our analysis**
5.4.2. Composition
5.4.3. Nanoparticle
5.4.4. Delivery
5.4.5. Lipid
5.4.6. Treatment
5.4.7. Drug
5.4.8. Formulation
5.4.9. System
5.4.10. Target
5.4.11. Compound
5.4.12. Therapeutic
5.4.13. Comprising
5.4.14. Protein
5.4.15. Peptide
5.4.16. Cancer
5.4.17. Conjugate
5.4.18. Carrier
5.4.19. Liposome
5.4.20. Nanocarrier
6.1. Overview
6.2. Parameters Analyzed
6.3. Patent Valuation Analysis
6.3.1. Analysis by Relative Valuation
6.3.2. Spider Web: Analysis of Value Ranks (Summary)
6.3.3. Analysis by Value Rank and Type of Patent
6.3.4. Analysis by Value Rank and Time to Expiry
6.3.5. Analysis by Value Rank and Number of Citations
6.3.6. Analysis by Value Rank and Geography
6.3.7. Spider Web: Detailed Analysis of Value Ranks
6.4. Analysis of Individual Value Ranks
6.4.1. Rank 1 IP Documents
6.4.1.1. Cumulative Trend of Patents
6.4.1.2. Analysis by Type of Patent
6.4.1.3. Analysis by Time to Expiry
6.4.1.4. Analysis by Number of Citations
6.4.1.5. Analysis by Patent Jurisdiction
** Similar details are presented for other below mentioned ranks based on our analysis**
6.4.2. Rank 2 IP Documents
6.4.3. Rank 3 IP Documents
6.4.4. Rank 4 IP Documents
6.4.5. Rank 5 IP Documents
6.5. Spider Web: Maximum, Minimum and Average Value Patents
7.1. Overview
7.2. Key Parameters
7.3. Lipid Nanoparticles in Drug Delivery: Patent Applications Landscape
7.3.1. Year-wise Trend of Patent Applications
7.3.2. Analysis by Validity of Claims
7.3.3. Analysis by Legal Status
7.3.4. Analysis by Innovation Type
7.3.5. Analysis by Application Area
7.3.6. Analysis by Innovation
7.3.7. Analysis by Therapeutic Area
7.4. Patent Valuation
7.4.1. Comparative Analysis of Value Ranks
7.4.2. Analysis by Value Rank and Time to Expiry
7.4.3. Analysis by Value Rank and Number of Citations
7.4.4. Analysis by Value Rank and Patent Jurisdiction
7.5. Patentability by Jurisdiction
7.5.1. North America
7.5.2. Europe
7.5.3. Asia-Pacific
7.5.4. Worldwide (WIPO)
7.6. Freedom to Operate in Innovations
7.6.1. Featuring Formation of Novel LNPs
7.6.2. Featuring LNP Based Drug Delivery Systems
7.6.3. Featuring Types of Lipid Nanoparticles
7.7. Summary of Innovations
7.7.1. Featuring Formation of Novel LNP
7.7.2. Featuring LNP Based Drug Delivery Systems
7.7.3. Featuring Types of Lipid Nanoparticles
7.7.4. Featuring Other Lipid Nanoparticle Advancements
8.1. Overview
8.2. Key Parameters
8.3. Lipid Nanoparticles in Drug Delivery: Granted Patents Landscape
8.3.1. Year-wise Trend of Granted Patents
8.3.2. Analysis by Validity of Claims
8.3.3. Analysis by Legal Status
8.3.4. Analysis by Innovation Type
8.3.5. Analysis by Application Area
8.3.6. Analysis by Innovation
8.3.7. Analysis by Therapeutic Area
8.4. Patent Valuation
8.4.1. Comparative Analysis of Value Ranks
8.4.2. Analysis by Value Rank and Time to Expiry
8.4.3. Analysis by Value Rank and Number of Citations
8.4.4. Analysis by Value Rank and Patent Jurisdiction
8.4.5. Analysis of Granted Patents by Value Rank
8.5. Patentability
8.5.1. North America
8.5.2. Europe
8.6. Freedom to Operate in Innovations
8.6.1. Featuring Formation of Novel LNPs
8.6.2. Featuring LNP Based Drug Delivery Systems
8.6.3. Featuring Types of Lipid Nanoparticles
8.7. Summary of Innovations
8.7.1. Featuring Formation of Novel LNP
8.7.2. Featuring LNP Based Drug Delivery Systems
8.7.3. Featuring Types of Lipid Nanoparticles
8.8. Claims Analysis: Overview
8.8.1. Analysis by Focus of Claims
8.8.2. Analysis by Number of Independent Claims
8.8.3. Analysis by Type of Claim
8.8.4. Analysis by Number of Elements
8.8.5. Analysis by Type of Innovation
8.8.6. Analysis by Innovation
8.8.7. Analysis by Application Area
8.8.8. Analysis by Therapeutic Area
9.1. Overview
9.2. Methodology
9.3. Key Applicants: Analysis by Number of Patents Published
9.4. Moderna
9.4.1. Company Overview
9.4.2. Leadership Team
9.4.3. Financial Information
9.4.4. Patent-related Insights
9.4.4.1. Analysis by Application Year
9.4.4.2. Analysis by Type of Patent
9.4.4.3. Analysis by Patent Jurisdiction
** Similar details are presented for other below mentioned applicants based on information available in public domain**
9.5. Flagship Pioneering
9.6. Avidity Biosciences
9.7. University of California
9.8. Alexion Pharmaceuticals
9.9. Biora Therapeutics
9.10. Massachusetts Institute of Technology
10.1. Overview of CPC Symbols
10.2. Objectives
10.3. Methodology
10.4. Analysis of CPC Families
10.4.1. Key Pockets of Innovation
10.4.2. CPC Symbols Associated with the A61P Family
10.4.2.1. Trend of IP Publication Featuring A61P35/00
10.4.2.2. Periodic Trend of CPC Usage
10.4.2.3. Analysis by Type of Patent
10.4.2.4. Analysis by Time to Expiry
10.4.2.5. Analysis by Patent Jurisdiction
** Similar details are presented for other below mentioned CPC symbols based on our analysis**
10.4.3. CPC Symbols Associated with the A61K Family (A61K9/5123)
10.4.4. CPC Symbols Associated with the A61K Family (A61K45/06)
10.4.5. CPC Symbols Associated with the A61K Family (A61K9/0019)
10.4.6. CPC Symbols Associated with the A61K Family (A61K9/127)
10.4.7. CPC Symbols Associated with the A61K Family (A61K9/1075)
10.4.8. CPC Symbols Associated with the A61K Family (A61K47/10)
10.4.9. CPC Symbols Associated with the A61K Family (A61K9/0014)
10.4.10. CPC Symbols Associated with the B82Y Family (B82Y5/00)
10.4.11. CPC Symbols Associated with the A61P Family (A61P43/00)
10.4.12. CPC Symbols Associated with the A61K Family (A61K9/1271)
10.4.13. CPC Symbols Associated with the A61K Family (A61K9/5192)
10.4.14. CPC Symbols Associated with the A61K Family (A61K38/00)
10.4.15. CPC Symbols Associated with the A61P Family (A61P29/00)
10.4.16. CPC Symbols Associated with the C12N Family (C12N15/113)
10.4.17. CPC Symbols Associated with the A61K Family (A61K9/5146)
10.4.18. CPC Symbols Associated with the A61K Family (A61K9/5153)
10.4.19. CPC Symbols Associated with the A61P Family (A61P25/00)
10.4.20. CPC Symbols Associated with the A61K Family (A61K2039/505)
10.4.21. CPC Symbols Associated with the A61K Family (A61K47/14)
11.1. Overview and Methodology
11.2. White Space Analysis
11.2.1. Innovations Featuring Formation of Novel LNPs
11.2.2. Innovations Featuring Types of Lipid Nanoparticles
11.2.3. Innovations Featuring LNP Based Drug Delivery Systems
12.1. Year-wise Trend of IP Publications
12.2. Trend of IP Publications across Type of Patent
12.3. Trend of IP Publications across Patent Jurisdiction
12.4. Historical, Current and Anticipated Future Developments related to Lipid Nanoparticles
13.1. Company A (Mid-sized Organization, US)
13.1.1. Interview Transcript: Bioengineering Professor
13.2. Company B (Very Large Company, Germany)
13.2.1. Interview Transcript: Formulation and Manufacturing Expert
13.3. Company C (Large Company, US)
13.3.1. Interview Transcript: Head of Intracellular Drug Delivery Centre
13.4. Company D (Mid-sized Company, Canada)
13.4.1. Interview Transcript: Director Business Development –Nucleic Acid Modalities
13.5. Company E (Mid-sized Company, Belgium)
13.5.1. Interview Transcript: Business Unit Director Nanomedicines – Research & Development
13.6. Company F (Mid-sized Company, Spain)
13.6.1. Interview Transcript: Sales Representative and Business Development Associate
Figure 2.1 Executive Summary: Overall Intellectual Property Landscape (Simply Family)
Figure 2.2 Executive Summary: Intellectual Property Valuation Analysis
Figure 2.3 Executive Summary: Prior Art Search Expressions
Figure 2.4 Executive Summary: Distribution of Patent Applications
Figure 2.5 Executive Summary: Distribution of Granted Patents
Figure 2.6 Executive Summary: Claim Analysis of Granted Patents
Figure 2.7 Executive Summary: Pockets of Innovation
Figure 2.8 Executive Summary: White Spaces
Figure 2.9 Executive Summary: Future Outlook
Figure 3.1 Historical Development of Lipid Nanoparticles
Figure 3.2 Lipid Nanoparticle Production Methods
Figure 3.3 Advantages of Lipid Nanoparticles
Figure 3.4 Key Application Areas of Lipid Nanoparticles
Figure 3.5 Challenges Associated with Lipid Nanoparticles Manufacturing
Figure 4.1 Overall Intellectual Property Landscape: Year-wise Trend of Patents
Figure 4.2 Overall Intellectual Property Landscape: Distribution by Patent Jurisdiction
Figure 4.3 Overall Intellectual Property Landscape: Distribution by Type of Patent
Figure 4.4 Overall Intellectual Property Landscape: Distribution by Kind Code
Figure 4.5 Overall Intellectual Property Landscape: Distribution by Time to Expiry
Figure 4.6 Simple Patent Family IP Landscape: Year-wise Trend of Patents
Figure 4.7 Simple Patent Family IP Landscape: Distribution by Validity of Claims
Figure 4.8 Simple Patent Family IP Landscape: Distribution by Type of Patent
Figure 4.9 Simple Patent Family IP Landscape: Distribution by Kind Code
Figure 4.10 Simple Patent Family IP Landscape: Distribution by Time to Expiry
Figure 4.11 Simple Patent Family IP Landscape: Distribution by Patent Jurisdiction
Figure 4.12 Simple Family Lipid Nanoparticles in Drug Delivery IP Landscape: Innovation Type
Figure 4.13 Simple Family Lipid Nanoparticles in Drug Delivery IP Landscape: Distribution of Patent Applications by Innovation Type
Figure 4.14 Simple Family Lipid Nanoparticles in Drug Delivery IP Landscape: Distribution of Granted Patents by Innovation Type
Figure 5.1 Frequently Used Search Expressions: Word Cloud
Figure 5.2 Prior Art Search Expressions: Frequently Used Prior Art Search Expressions
Figure 5.3 Prior Art Search Expressions: Key IP Trends Associated with the Word - Method
Figure 5.4 Prior Art Search Expressions: Key IP Trends Associated with the Word - Composition
Figure 5.5 Prior Art Search Expressions: Key IP Trends Associated with the Word - Nanoparticle
Figure 5.6 Prior Art Search Expressions: Key IP Trends Associated with the Word - Delivery
Figure 5.7 Prior Art Search Expressions: Key IP Trends Associated with the Word - Lipid
Figure 5.8 Prior Art Search Expressions: Key IP Trends Associated with the Word - Treatment
Figure 5.9 Prior Art Search Expressions: Key IP Trends Associated with the Word - Drug
Figure 5.10 Prior Art Search Expressions: Key IP Trends Associated with the Word - Formulation
Figure 5.11 Prior Art Search Expressions: Key IP Trends Associated with the Word - System
Figure 5.12 Prior Art Search Expressions: Key IP Trends Associated with the Word - Target
Figure 5.13 Prior Art Search Expressions: Key IP Trends Associated with the Word - Compound
Figure 5.14 Prior Art Search Expressions: Key IP Trends Associated with the Word - Therapeutic
Figure 5.15 Prior Art Search Expressions: Key IP Trends Associated with the Word - Comprising
Figure 5.16 Prior Art Search Expressions: Key IP Trends Associated with the Word - Protein
Figure 5.17 Prior Art Search Expressions: Key IP Trends Associated with the Word - Peptide
Figure 5.18 Prior Art Search Expressions: Key IP Trends Associated with the Word - Cancer
Figure 5.19 Prior Art Search Expressions: Key IP Trends Associated with the Word - Conjugate
Figure 5.20 Prior Art Search Expressions: Key IP Trends Associated with the Word - Carrier
Figure 5.21 Prior Art Search Expressions: Key IP Trends Associated with the Word - Liposome
Figure 5.22 Prior Art Search Expressions: Key IP Trends Associated with the Word - Nanocarrier
Figure 6.1 Patent Valuation Analysis: Distribution by Relative Valuation
Figure 6.2 Spider Web: Analysis of Value Ranks (Summary)
Figure 6.3 Patent Valuation Analysis: Distribution by Value Rank and Type of Patent
Figure 6.4 Patent Valuation Analysis: Distribution by Value Rank and Time to Expiry
Figure 6.5 Patent Valuation Analysis: Distribution by Value Rank and Number of Citations
Figure 6.6 Patent Valuation Analysis: Distribution by Value Rank and Geography
Figure 6.7 Spider Web: Detailed Analysis of Value Ranks
Figure 6.8 Analysis of Individual Value Ranks: Rank 1 IP Documents
Figure 6.9 Analysis of Individual Value Ranks: Rank 2 IP Documents
Figure 6.10 Analysis of Individual Value Ranks: Rank 3 IP Documents
Figure 6.11 Analysis of Individual Value Ranks: Rank 4 IP Documents
Figure 6.12 Analysis of Individual Value Ranks: Rank 5 IP Documents
Figure 6.13 Spider Web: Maximum, Minimum and Average Value Patents
Figure 7.1 Patent Applications Landscape: Year-wise Trend of Patent Applications
Figure 7.2 Patent Applications Landscape: Distribution by Patent Applications
Figure 7.3 Spider Web: Detailed Analysis of Value Ranks
Figure 7.4 Patent Valuation: Distribution by Value Rank and Time to Expiry
Figure 7.5 Patent Valuation: Distribution by Value Rank and Number of Citations
Figure 7.6 Patent Valuation: Distribution by Value Rank and Jurisdiction
Figure 7.7 Patent Applications Landscape: Patentability in North America
Figure 7.8 Patent Applications Landscape: Patentability in Europe
Figure 7.9 Patent Applications Landscape: Patentability in Asia-Pacific
Figure 7.10 Patent Applications Landscape: Patentability Worldwide (WIPO)
Figure 7.11 Patent Applications Landscape: Freedom to Operate in Innovations Featuring Formation of Novel LNPs
Figure 7.12 Patent Applications Landscape: Freedom to Operate in Innovations Featuring LNP Based Drug Delivery Systems
Figure 7.13 Patent Applications Landscape: Freedom to Operate in Innovations Featuring Types of Lipid Nanoparticles
Figure 8.1 Granted Patents Landscape: Year-wise Trend of Granted Patents
Figure 8.2 Granted Patents Landscape: Distribution by Granted Patents
Figure 8.3 Spider Web: Detailed Analysis of Value Ranks
Figure 8.4 Patent Valuation: Distribution by Value Rank and Time to Expiry
Figure 8.5 Patent Valuation: Distribution by Value Rank and Number of Citations
Figure 8.6 Patent Valuation: Distribution by Value Rank and Jurisdiction
Figure 8.7 Patent Valuation: Distribution of Granted Patents by Value Rank
Figure 8.8 Granted Patents Landscape: Patentability in North America
Figure 8.9 Granted Patents Landscape: Patentability in Europe
Figure 8.10 Granted Patents Landscape: Freedom to Operate in Innovations Featuring Formation of Novel LNPs
Figure 8.11 Granted Patents Landscape: Freedom to Operate in Innovations Featuring LNP Based Drug Delivery Systems
Figure 8.12 Granted Patents Landscape: Freedom to Operate in Innovations Featuring Types of Lipid Nanoparticles
Figure 8.13 Claims Analysis: Distribution by Focus of Claims
Figure 8.14 Claims Analysis: Distribution by Independent Claims
Figure 8.15 Claims Analysis: Distribution by Type of Claim
Figure 8.16 Claims Analysis: Distribution by Number of Elements
Figure 8.17 Claims Analysis: Distribution by Type of Innovation
Figure 8.18 Claims Analysis: Distribution by Innovation
Figure 8.19 Claims Analysis: Distribution by Application Area
Figure 8.20 Claims Analysis: Distribution by Therapeutic Area
Figure 9.1 Key Applicants: Distribution by Number of Patents Published
Figure 9.2 Moderna: Financial Information (USD Billion)
Figure 9.3 Moderna: Patent-related Insights
Figure 9.4 Flagship Pioneering: Patent-related Insights
Figure 9.5 Avidity Biosciences: Financial Information (USD Million)
Figure 9.6 Avidity Biosciences: Patent-related Insights
Figure 9.7 University of California: Patent-related Insights
Figure 9.8 AstraZeneca (Parent Company of Alexion Pharmaceuticals): Financial Information (USD Billion)
Figure 9.9 Alexion Pharmaceuticals: Patent-related Insights
Figure 9.10 Biora Therapeutics: Financial Information (USD Million)
Figure 9.11 Biora Therapeutics: Patent-related Insights
Figure 9.12 Massachusetts Institute of Technology: Patent-related Insights
Figure 10.1 Analysis of CPC Families: Key Pockets of Innovation
Figure 10.2 Analysis of CPC Families: CPC Symbols Associated with the A61P Family (A61P35/00)
Figure 10.3 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/5123)
Figure 10.4 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K45/06)
Figure 10.5 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/0019)
Figure 10.6 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/127)
Figure 10.7 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/1075)
Figure 10.8 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K47/10)
Figure 10.9 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/0014)
Figure 10.10 Analysis of CPC Families: CPC Symbols Associated with the B82Y Family (B82Y5/00)
Figure 10.11 Analysis of CPC Families: CPC Symbols Associated with the A61P Family (A61P43/00)
Figure 10.12 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/1271)
Figure 10.13 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/5192)
Figure 10.14 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K38/00)
Figure 10.15 Analysis of CPC Families: CPC Symbols Associated with the A61P Family (A61P29/00)
Figure 10.16 Analysis of CPC Families: CPC Symbols Associated with the C12N Family (C12N15/113)
Figure 10.17 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/5146)
Figure 10.18 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K9/5153)
Figure 10.19 Analysis of CPC Families: CPC Symbols Associated with the A61P Family (A61P25/00)
Figure 10.20 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K2039/505)
Figure 10.21 Analysis of CPC Families: CPC Symbols Associated with the A61K Family (A61K47/14)
Figure 11.1 White Space Analysis: Innovations Featuring Formation of Novel LNPs
Figure 11.2 White Space Analysis: Innovations Featuring Types of Lipid Nanoparticles
Figure 11.3 White Space Analysis: Innovations Featuring LNP Based Drug Delivery Systems
Figure 12.1 Lipid Nanoparticles in Drug Delivery IP Landscape: Year-wise Trend of IP Publications
Table 6.1 Intellectual Property Valuation Analysis: Information on Net Scores
Table 6.2 Lipid Nanoparticles in Drug Delivery: Rank 1 IP Documents
Table 7.1 Analysis of Patent Applications: Information on Net Scores
Table 8.1 Analysis of Granted Patents: Information on Net Scores
Please reach out to our team for more details.